Logo image of SGMO

SANGAMO THERAPEUTICS INC (SGMO) Stock Fundamental Analysis

NASDAQ:SGMO - Nasdaq - US8006771062 - Common Stock - Currency: USD

0.7283  -0.01 (-1.74%)

After market: 0.7399 +0.01 (+1.59%)

Fundamental Rating

2

Overall SGMO gets a fundamental rating of 2 out of 10. We evaluated SGMO against 566 industry peers in the Biotechnology industry. The financial health of SGMO is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SGMO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SGMO has reported negative net income.
SGMO had a negative operating cash flow in the past year.
SGMO had negative earnings in each of the past 5 years.
In the past 5 years SGMO reported 4 times negative operating cash flow.
SGMO Yearly Net Income VS EBIT VS OCF VS FCFSGMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

The Return On Assets of SGMO (-144.66%) is worse than 84.28% of its industry peers.
SGMO's Return On Equity of -645.72% is on the low side compared to the rest of the industry. SGMO is outperformed by 81.63% of its industry peers.
Industry RankSector Rank
ROA -144.66%
ROE -645.72%
ROIC N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
SGMO Yearly ROA, ROE, ROICSGMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SGMO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMO Yearly Profit, Operating, Gross MarginsSGMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
SGMO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SGMO has been increased compared to 5 years ago.
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGMO Yearly Shares OutstandingSGMO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
SGMO Yearly Total Debt VS Total AssetsSGMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

SGMO has an Altman-Z score of -23.51. This is a bad value and indicates that SGMO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SGMO (-23.51) is worse than 88.16% of its industry peers.
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.51
ROIC/WACCN/A
WACC10.04%
SGMO Yearly LT Debt VS Equity VS FCFSGMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

SGMO has a Current Ratio of 1.13. This is a normal value and indicates that SGMO is financially healthy and should not expect problems in meeting its short term obligations.
SGMO has a Current ratio of 1.13. This is amonst the worse of the industry: SGMO underperforms 87.10% of its industry peers.
SGMO has a Quick Ratio of 1.13. This is a normal value and indicates that SGMO is financially healthy and should not expect problems in meeting its short term obligations.
SGMO's Quick ratio of 1.13 is on the low side compared to the rest of the industry. SGMO is outperformed by 85.51% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
SGMO Yearly Current Assets VS Current LiabilitesSGMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

SGMO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.63%, which is quite impressive.
The Revenue for SGMO has decreased by -66.93% in the past year. This is quite bad
The Revenue for SGMO have been decreasing by -10.81% on average. This is quite bad
EPS 1Y (TTM)64.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.65%
Revenue 1Y (TTM)-66.93%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%269.78%

3.2 Future

The Earnings Per Share is expected to grow by 13.01% on average over the next years. This is quite good.
SGMO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.40% yearly.
EPS Next Y12.22%
EPS Next 2Y14.97%
EPS Next 3Y27.42%
EPS Next 5Y13.01%
Revenue Next Year-11.89%
Revenue Next 2Y0.86%
Revenue Next 3Y41.26%
Revenue Next 5Y40.4%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SGMO Yearly Revenue VS EstimatesSGMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
SGMO Yearly EPS VS EstimatesSGMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SGMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SGMO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMO Price Earnings VS Forward Price EarningsSGMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMO Per share dataSGMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

SGMO's earnings are expected to grow with 27.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.97%
EPS Next 3Y27.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGMO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (5/2/2025, 8:23:02 PM)

After market: 0.7399 +0.01 (+1.59%)

0.7283

-0.01 (-1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners29.58%
Inst Owner Change0.41%
Ins Owners1.09%
Ins Owner Change-3.53%
Market Cap163.66M
Analysts78.57
Price Target5.1 (600.26%)
Short Float %13.56%
Short Ratio4.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)109.54%
Min EPS beat(2)-18.18%
Max EPS beat(2)237.26%
EPS beat(4)1
Avg EPS beat(4)43.53%
Min EPS beat(4)-23.84%
Max EPS beat(4)237.26%
EPS beat(8)2
Avg EPS beat(8)13.77%
EPS beat(12)6
Avg EPS beat(12)12.84%
EPS beat(16)8
Avg EPS beat(16)10.87%
Revenue beat(2)1
Avg Revenue beat(2)62.17%
Min Revenue beat(2)-45.63%
Max Revenue beat(2)169.98%
Revenue beat(4)1
Avg Revenue beat(4)-16.09%
Min Revenue beat(4)-95.77%
Max Revenue beat(4)169.98%
Revenue beat(8)2
Avg Revenue beat(8)42.2%
Revenue beat(12)4
Avg Revenue beat(12)29.35%
Revenue beat(16)8
Avg Revenue beat(16)23.36%
PT rev (1m)0%
PT rev (3m)-21.05%
EPS NQ rev (1m)1.6%
EPS NQ rev (3m)-164.53%
EPS NY rev (1m)-6.55%
EPS NY rev (3m)-118.29%
Revenue NQ rev (1m)79.78%
Revenue NQ rev (3m)-39.46%
Revenue NY rev (1m)2.33%
Revenue NY rev (3m)-14.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.81
P/FCF N/A
P/OCF N/A
P/B 7.19
P/tB 7.19
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0.26
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -144.66%
ROE -645.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.23%
Cap/Sales 0.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z -23.51
F-Score3
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)104.2%
Cap/Depr(5y)163.67%
Cap/Sales(3y)10.21%
Cap/Sales(5y)12.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.65%
EPS Next Y12.22%
EPS Next 2Y14.97%
EPS Next 3Y27.42%
EPS Next 5Y13.01%
Revenue 1Y (TTM)-66.93%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%269.78%
Revenue Next Year-11.89%
Revenue Next 2Y0.86%
Revenue Next 3Y41.26%
Revenue Next 5Y40.4%
EBIT growth 1Y-40.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year115%
EBIT Next 3Y48.65%
EBIT Next 5Y28.54%
FCF growth 1Y72.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A